title: Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
abstract: BACKGROUND
  Advanced malignancies that are refractory to standard chemotherapy have few treatment options. Conatumumab is an investigational, fully human monoclonal agonist antibody directed at human death receptor DR5, which is expressed in multiple advanced cancers.
  
  
  METHODS
  The rationale for the use of conatumumab based on in vitro, in vivo, Phase I, and Phase II data will be discussed.
  
  
  CONCLUSIONS
  Conatumumab, at a dose of 20 mg/kg every 2 weeks, has demonstrated acceptable safety and tolerability in patients with advanced tumors based on available and published data. Further clinical trials are underway evaluating the use of conatumumab in combination with chemotherapeutic and targeted agents.
authors: Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA.
authors: Madhuri
authors: M
authors: Bajaj
authors: Elisabeth I
authors: EI
authors: Heath
mesh_terms: D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; C554537:conatumumab